Skip to content
Clinical Trials – home

Area De Salud De Burgos Y Soria

Research site

Spain Avenida De Las Islas Baleares 3, 09006 Burgos, Spain

  • 34 trials recruiting
  • Immune thrombocytopenia · Acute myeloid leukaemia · Huntington's disease
  • Adults and children

About Specializations

Area De Salud De Burgos Y Soria in Burgos, Spain specialises in clinical trials of conditions such as Immune thrombocytopenia, Acute myeloid leukaemia, Huntington's disease, Breast cancer, and other specialisations. This site conducts important research.

Main research areas of the site

Oncology Research

At Area De Salud De Burgos Y Soria, the Oncology department is running a broad portfolio of trials focused on neoplasms and related blood cancers. Research here includes studies aimed at improving treatment outcomes for breast cancer, lung cancer, colorectal cancer, gastric cancer, and several forms of lymphoma and leukemia.

  • Trials evaluating new treatment strategies for early and advanced breast cancer, including hormone receptor-positive and HER2-related disease
  • Studies in hematologic malignancies such as multiple myeloma, acute myeloid leukemia, chronic lymphocytic leukemia, and lymphoma
  • Research in solid tumors, including non-small cell lung cancer, hepatocellular carcinoma, head and neck cancer, and gastrointestinal cancers

Much of the work at this hospital/clinic site is designed to test new therapies, compare them with current standards, and improve long-term disease control, survival, and relapse prevention in patients with cancer.

Blood Disorders and Immune-Related Conditions

A major research focus at the site covers hemic and lymphatic diseases as well as selected immune system diseases. These trials study conditions such as immune thrombocytopenia, warm autoimmune hemolytic anemia, and other autoimmune cytopenias, with the goal of finding better ways to restore blood counts and reduce bleeding or anemia.

  • Studies testing therapies for immune thrombocytopenia and primary immune thrombocytopenia
  • Research on autoimmune hemolytic anemia and broader autoimmune cytopenias
  • Trials in lymphoma and myeloma that aim to improve response rates and disease control

This area of research is centered on evaluating treatment effectiveness and safety in disorders where the immune system affects the blood, while also exploring options that may reduce the need for rescue treatment.

Neurology and Mental Health

The site also participates in studies within nervous system diseases and psychiatry and psychology. Key conditions include Huntington’s disease, Parkinson’s disease, schizophrenia, autism spectrum disorders, and Tourette syndrome, reflecting a strong interest in both movement and behavioral disorders.

  • Trials seeking to slow progression or improve symptoms in Huntington’s disease and Parkinson’s disease
  • Studies focused on schizophrenia and cognitive or negative symptoms
  • Research in autism spectrum disorders and Tourette syndrome aimed at improving communication, behavior, and quality of life

These investigations are mainly intended to assess symptom control, functional improvement, and the long-term safety of emerging or repurposed treatments.

Respiratory, Allergic, and Infectious Diseases

Clinical research at this site extends into respiratory tract diseases, bacterial infections and mycoses, and virus diseases. Trials include studies in chronic obstructive pulmonary disease, eosinophilic asthma, allergic rhinoconjunctivitis, respiratory syncytial virus infections, and serious bacterial or fungal infections.

  • Studies evaluating better control of COPD and asthma
  • Research on allergic rhinitis and allergic rhinoconjunctivitis to improve seasonal symptom relief
  • Trials in infectious diseases such as P. aeruginosa bacteremia, fungal infections, and RSV

The purpose of this research is to improve diagnosis and treatment effectiveness, while also reducing complications and treatment burden in patients with chronic or acute respiratory and infectious conditions.

Cardiovascular, Kidney, and Acute Care Research

Another important research area includes cardiovascular diseases, digestive system diseases, and pathological conditions seen in acute care. Trials cover acute pulmonary embolism, acute myocarditis, heart failure, chronic kidney disease, end-stage kidney disease, and preeclampsia.

  • Studies aimed at improving management of pulmonary embolism, myocarditis, and heart failure
  • Research on kidney disease and dialysis-related care
  • Trials in acute and supportive care, including postoperative pain and metabolic complications

These trials generally focus on testing whether existing or new approaches can improve clinical outcomes, reduce complications, and support safer care for patients with complex medical needs.

Other Areas of Clinical Investigation

Beyond its main oncology focus, the site contributes to studies in ophthalmology, urology, gastroenterology, and pharmacogenetics. Research topics include wet age-related macular degeneration, prostate cancer, ulcerative colitis, recurrent pancreatitis, and the use of genetic information to personalize treatment.

  • Trials exploring eye disease treatments to preserve vision in neovascular AMD
  • Studies in prostate cancer and digestive disorders such as ulcerative colitis
  • Research on pharmacogenetics to improve medication choice and reduce adverse reactions

This diverse portfolio shows a strong interest in treatment optimization across both common and specialized conditions, with an emphasis on practical benefits for patients and clinicians.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Avenida De Las Islas Baleares 309006 BurgosSpain
Recruiting now
34 trials
Conditions studied
62

More sites in BurgosSpain

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

87 clinical trials

Randomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Study of sotorasib, panitumumab and a drug combination for patients with metastatic colorectal cancer with KRAS p.G12C mutation.

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Bevacizumab
  • Sponsor:Amgen Inc.

Study of Ifinatamab Deruxtecan and Chemotherapy for Patients with Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Daiichi Sankyo Inc.

Schizophrenia

Recruiting

Study on Vafidemstat for Treating Negative Symptoms and Cognitive Impairment in Adults with Schizophrenia

Investigational
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Vafidemstat
  • Sponsor:Oryzon Genomics S.A.

Influenza+1

Recruiting

Efficacy and safety of the investigational mRNA influenza vaccine gskvx000000077430 (drug combination) in adults ≥ 65 years

Registered drugNo placebo
Countries:SpainSpain
  • Participants:65+ years · Healthy volunteers
  • Substances:INFLUENZA A VIRUS, A/CROATIA/10136RV/2023 (H3N2) LIKE STRAIN X-425A, INACTIVATED
  • Sponsor:GlaxoSmithKline Biologicals

Efficacy and safety of votoplam in adults with Huntington’s disease: a randomized, double‑blind, placebo‑controlled Phase 3 trial

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Votoplam
  • Sponsor:Novartis Pharma AG

Mesalazine Monotherapy vs Continuing Thiopurines in Older Patients with Ulcerative Colitis in Long-Term Remission

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Mesalazine

A study to evaluate the safety and efficacy of ivosidenib, decitabine, and cedazuridine in adults with newly diagnosed acute myeloid leukemia who are older than 60 or cannot receive intensive chemotherapy.

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cedazuridine
  • Sponsor:Fundacion PETHEMA

Study of ziftomenib with drug combinations for adults with newly diagnosed acute myeloid leukemia with NPM1 or KMT2A genetic changes

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Kura Oncology Inc.

Mite allergy

Recruiting

A study testing dust mite allergy extracts from Dermatophagoides pteronyssinus and Dermatophagoides farinae for patients with allergic rhinoconjunctivitis with or without controlled asthma

Registered drug
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:LETI Pharma S.L.U.

Study of Revumenib and Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia with NPM1 Gene Mutation

Registered drug
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Syndax Pharmaceuticals Inc.

A study comparing venetoclax, azacitidine, and quizartinib versus venetoclax and azacitidine in newly diagnosed acute myeloid leukemia patients not suitable for standard chemotherapy

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Quizartinib Dihydrochloride
  • Sponsor:Fundacion PETHEMA
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.